At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
In Brief
A Phase 2 clinical trial evaluating LASN01 and Placebo for Thyroid Eye Disease and 7 related conditions. Completed, enrolled 41 participants across 15 sites in 3 countries.
Detailed Summary
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED). The primary and secondary objectives of this study are to evaluate the treatment effect, safety, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.
Study Details
Timeline
Interventions
Low dose of LASN01 will be administered intravenously.
High dose of LASN01 will be administered intravenously.
Placebo will be administered intravenously.
High dose of LASN01 will be administered intravenously.